ImCheck Therapeutics ImCheck Therapeutics ImCheck Therapeutics

ImCheck Therapeutics

Immuno-oncology

ImCheck Therapeutics was founded in 2015 as a spinoff from the Paoli-Calmettes Cancer Institute in Marseille (France). The biotech company is developing innovative antibody therapeutics in the field of immuno-oncology, based on scientific assets originating from the pioneering work of Prof. Daniel Olive. The company is in Phase I/II clinical trials with its lead program.

Life Sciences

Visit website

Investment  details

Entry

2017

Staff

Location

France

At ImCheck, we're proud to have Gimv as a key investor who shares our belief in the game-changing potential of our innovative antibody therapeutics in immuno-oncology.

Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

ImCheck has the potential to fundamentally change the treatment of certain types of cancer. Gimv's investment will make it possible to drive forward the clinical development of the drug candidates and further research programmes.